How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...
On February 5, 2026, OpenAI introduced GPT-5.3-Codex and wrote in its release notes that early versions of the model were “instrumental in creating itself,” helping to debug training runs, manage ...
Abstract: This paper studies the estimation of dynamic route choice behavior of drivers with incomplete fixed location-based sensor data, such as radio frequency identification (RFID) data. Unlike ...
Abstract: Decentralized cooperative localization (DCL) is a promising method to determine accurate multirobot poses (i.e., positions and orientations) for robot teams operating in an environment ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
2024-02-04: Code and pre-trained models are released. 🎊🎊🎊 2023-09-29: This repo is released. Download training and testing datasets and put them into the corresponding folders of datasets/. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results